HRP20140442T1 - Metoda za pripremu spoja 1,3-propan disulfonske kiseline - Google Patents
Metoda za pripremu spoja 1,3-propan disulfonske kiseline Download PDFInfo
- Publication number
- HRP20140442T1 HRP20140442T1 HRP20140442TT HRP20140442T HRP20140442T1 HR P20140442 T1 HRP20140442 T1 HR P20140442T1 HR P20140442T T HRP20140442T T HR P20140442TT HR P20140442 T HRP20140442 T HR P20140442T HR P20140442 T1 HRP20140442 T1 HR P20140442T1
- Authority
- HR
- Croatia
- Prior art keywords
- disulfonic acid
- propane disulfonic
- acid compound
- compound
- bromo
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 24
- 229940079593 drug Drugs 0.000 title 1
- -1 1,3-propane disulfonic acid compound Chemical class 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 6
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims 4
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 claims 4
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims 4
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 claims 4
- JSAYPSXBCDUDKB-UHFFFAOYSA-M 3-bromopropane-1-sulfonate Chemical compound [O-]S(=O)(=O)CCCBr JSAYPSXBCDUDKB-UHFFFAOYSA-M 0.000 claims 4
- 239000006227 byproduct Substances 0.000 claims 4
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims 4
- MGNVWUDMMXZUDI-UHFFFAOYSA-N propane-1,3-disulfonic acid Chemical compound OS(=O)(=O)CCCS(O)(=O)=O MGNVWUDMMXZUDI-UHFFFAOYSA-N 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 3
- 230000003941 amyloidogenesis Effects 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000023769 AA amyloidosis Diseases 0.000 claims 1
- 208000023761 AL amyloidosis Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 150000001649 bromium compounds Chemical class 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 239000012038 nucleophile Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 150000008053 sultones Chemical group 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Claims (21)
1. Metoda za pripremu spoja1,3-propan disulfonske kiseline izborom 1,3-propan disulfonske kiseline i farmaceutski prihvatljivih soli 1,3-propan disulfonske kiseline, u kojem postupak obuhvaća otvaranje sultonskog prstena sa sufitnim ajnonom kao nukleofilom, sa ciljem da se proizvede spoj 1,3-propan disulfonske kiseline.
2. Metoda patentnog zahtjeva 1, gdje je spoj1,3-propan disulfonske kiseline dinatrijumova sol 1,3-propan disulfonske kiseline.
3. Metoda patentnih zahtjeva 1 ili 2, koji podrazumijeva vodu kao otapalo.
4. Metoda patentnog zahtjeva 3, koji dalje podrazumijeva aceton kao ko-otapalo.
5. Metoda bilo kojeg prethodnog patentnog zahtjeva, gdje je kapacitet prinosa veći ili jednak 2%.
6. Metoda patentnog zahtjeva 5, gdje je kapacitet prinosa veći ili jednak 5%.
7. Metoda bilo kojeg prethodnog patentnog zahtjeva, koji dalje obuhvaća mjeru pročišćavanja spoja1,3-propan disulfonske kiseline.
8. Metoda bilo kojeg prethodnog patentnog zahtjeva, u kojemspoj1,3-propan disulfonske kiseline ne sadrži bromide.
9. Metoda bilo kojeg prethodnog patentnog zahtjeva, u kojemspoj1,3-propan disulfonske kiseline ne sadrži natrij.
10. Metoda bilo kojeg prethodnog patentnog zahtjeva, u kojem spoj 1,3-propan disulfonske kiseline ima sadržaj sulfata manji od 1.4%.
11. Metoda patentnog zahtjeva 10, u kojem jedinjenje 1,3-propan disulfonske kiseline ima sadržaj sulfata manji od 1.0%.
12. Metoda patentnog zahtjeva 11, u kojem jedinjenje 1,3-propan disulfonske kiseline ima sadržaj sulfata manji od 0.5%,kao što je manje od0.2%.
13. Metoda bilo kojeg prethodnog patentnog zahtjeva, u kojem spoj 1,3-propan disulfonske kiseline ne sadrži bar jedan od sporednih proizvoda izabranih iz grupe koja sadrži 1,3-propandiol, 3-brom-1-propanol, 1,3-dibrompropan, i 3-brom-propansulfonat.
14. Metoda patentnog zahtjeva 13, u kojem spoj 1,3-propan disulfonske kiseline ne sadrži bar dva sporedna proizvoda izabrana iz grupe koja sadrži 1,3-propandiol, 3-brom-1-propanol, 1,3-dibrompropan, i 3-brom-propansulfonat.
15. Metoda patentnog zahtjeva 13,u kojem spoj 1,3-propan disulfonske kiseline ne sadrži bar tri sporedna proizvoda izabrana iz grupe koja sadrži 1,3-propandiol, 3-brom-1-propanol, 1,3-dibrompropan, i 3-brom-propansulfonat.
16. Metoda patentnog zahtjeva 13,u kojemspoj 1,3-propan disulfonske kiselinene sadrži četiri sporedna proizvoda 1,3-propandiol, 3-brom-1-propanol, 1,3-dibrompropan, and3-brom-propansulfonat.
17. Metoda pripreme farmaceutskog spoja koji obuhvaća spoj 1,3-propan disulfonske kiselinei farmaceutski prihvatljiv nosač, obuhvaćajući pripremuspoja 1,3-propan disulfonske kiseline prema metodi bilo kojeg prethodnog patentnog zahtjeva; kombinirajućispoj 1,3-propan disulfonske kiseline sa farmaceutski prihvatljivim nosačem, formirajući farmaceutski spoj.
18. Metoda patentnog zahtjeva 17, u kojem je spoj u uporabi za inhibiciju taloženja amiloida u subjektu.
19. Metoda patentnog zahtjeva 17, u kojem je spoj u uporabi za liječenje amiloidoze u subjektu.
20. Metoda patentnog zahtjeva 17, u kojem je jedinjenje u uporabi za liječenje ili prevenciju bolesti prouzrokovanih taloženjem amiloida u subjektu.
21. Metoda patentnog zahtjeva 20, u kojem su bolesti prouzrokovane taloženjem amiloida izabrane iz grupe koja sadrži Alzheimerovu bolest, cerebralnu amiloidnu angiopatiju, inkluzioni miozitis, degeneraciju makule, AA amiloidozu, AL amiloidozu, Downov sindrom, blago kognitivno oštećenje, dijabetes tipa II i nasljednu cerebralnu hemoragiju.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48205803P | 2003-06-23 | 2003-06-23 | |
| US48090603P | 2003-06-23 | 2003-06-23 | |
| US51213503P | 2003-10-17 | 2003-10-17 | |
| US51204703P | 2003-10-17 | 2003-10-17 | |
| US10/871,514 US7414076B2 (en) | 2003-06-23 | 2004-06-18 | Methods and compositions for treating amyloid-related diseases |
| US10/871,543 US7253306B2 (en) | 2003-06-23 | 2004-06-18 | Pharmaceutical drug candidates and methods for preparation thereof |
| PCT/IB2004/002563 WO2004113391A2 (en) | 2003-06-23 | 2004-06-21 | Improved pharmaceutical drug candidates and methods for preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140442T1 true HRP20140442T1 (hr) | 2014-07-04 |
Family
ID=38987140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140442TT HRP20140442T1 (hr) | 2003-06-23 | 2014-05-19 | Metoda za pripremu spoja 1,3-propan disulfonske kiseline |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20080027097A1 (hr) |
| JP (1) | JP2012176963A (hr) |
| HK (1) | HK1090655A1 (hr) |
| HR (1) | HRP20140442T1 (hr) |
| IL (1) | IL172250A0 (hr) |
| SI (1) | SI1646659T1 (hr) |
| TW (1) | TW200517367A (hr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040208875A1 (en) * | 1995-03-15 | 2004-10-21 | Queen's University At Kingston | Method for treating amyloidosis |
| WO2001003680A2 (en) * | 1999-07-09 | 2001-01-18 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
| US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| BR112014016193A8 (pt) | 2011-12-29 | 2017-07-04 | Omrix Biopharmaceuticals Ltd | método e dispositivo para dissilução rápida |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2693488A (en) * | 1950-08-30 | 1954-11-02 | Dow Chemical Co | Purification of amino alkane sulfonic acids by ion exchange |
| US3658966A (en) * | 1969-09-15 | 1972-04-25 | Kowa Co | Methods of treating hypertension |
| US4085134A (en) * | 1974-02-15 | 1978-04-18 | Petrolite Corporation | Amino-phosphonic-sulfonic acids |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| US5972328A (en) * | 1993-03-29 | 1999-10-26 | Queen's University At Kingston | Method for treating amyloidosis |
| WO2000027807A1 (en) * | 1998-11-10 | 2000-05-18 | Neurochem, Inc. | Polymorphic forms of an amyloidosis inhibitor and methods of preparation |
| US6562836B1 (en) * | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
-
2004
- 2004-06-21 SI SI200432160T patent/SI1646659T1/sl unknown
- 2004-06-23 TW TW093118182A patent/TW200517367A/zh unknown
-
2005
- 2005-11-29 IL IL172250A patent/IL172250A0/en not_active IP Right Cessation
-
2006
- 2006-10-17 HK HK06111373.8A patent/HK1090655A1/xx not_active IP Right Cessation
-
2007
- 2007-07-11 US US11/776,407 patent/US20080027097A1/en not_active Abandoned
-
2010
- 2010-07-23 US US12/842,990 patent/US20110021813A1/en not_active Abandoned
-
2012
- 2012-05-02 JP JP2012104999A patent/JP2012176963A/ja active Pending
-
2014
- 2014-05-19 HR HRP20140442TT patent/HRP20140442T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20080027097A1 (en) | 2008-01-31 |
| IL172250A0 (en) | 2006-04-10 |
| SI1646659T1 (sl) | 2014-07-31 |
| JP2012176963A (ja) | 2012-09-13 |
| TW200517367A (en) | 2005-06-01 |
| HK1090655A1 (en) | 2006-12-29 |
| US20110021813A1 (en) | 2011-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140442T1 (hr) | Metoda za pripremu spoja 1,3-propan disulfonske kiseline | |
| CN109528721B (zh) | 联合治疗 | |
| HRP20150056T1 (hr) | Soli clopidogrela i postupak pripreme | |
| DE3850676T2 (de) | Hypotensive okulare Mittel. | |
| EP1784388B8 (en) | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | |
| JP2007516983A5 (hr) | ||
| EP2743259B1 (en) | Method for purifying (s)-oxiracetam | |
| RU93049997A (ru) | Производные метилен-бис-фосфоновой кислоты, способ их получения, фармацевтическая композиция | |
| BR0011403A (pt) | Processos para a purificação e para a preparação de ácido acrìlico ou ácido metacrìlico | |
| AU2023208158A1 (en) | Compositions and methods for the treatment of cancer | |
| CN1872841A (zh) | 瑞舒伐他汀钙及其关键中间体的制备方法 | |
| JP5826371B2 (ja) | ペメトレキセド塩の製造方法 | |
| CN101023077B (zh) | 生产对映体咪唑化合物的方法 | |
| EP2743258B1 (en) | Method for purifying levo-oxiracetam | |
| CN103288801B (zh) | 一种高纯度埃索美拉唑钠的制备方法 | |
| TW202237087A (zh) | 作為醫藥活性化合物之大麻素衍生物及其製備方法 | |
| CN102898418A (zh) | 埃索美拉唑镁的制备方法 | |
| CN109867685B (zh) | 一种硫酸氢氯吡格雷ii型的制备方法 | |
| ES2753403T3 (es) | Procedimiento para la obtención de enantiómeros de pirlindol ópticamente activos y sales de los mismos | |
| JP2008509104A5 (hr) | ||
| HRP20120926T1 (hr) | Stereoselektivni postupak i kristalni oblici kamptotecina | |
| JPS62221659A (ja) | アミノ置換安息香酸 | |
| JP2008526789A (ja) | タウリンの合成、生成及び医薬としての利用 | |
| DE69104485T2 (de) | Von dialkylaminoalkyl-26-sulfonylpristinamycin iib abgeleitete salze. | |
| CN102229616A (zh) | 四氢噻吩并吡啶衍生物及其制备方法和用途 |